Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE

Publication Details

Clinical Medicine Insights: Cardiology

April 2026

Access Here

Author(s)

Jose Nativi-Nicolau¹, Johana Fajardo², Alyssa Galloway^{3 4}, Sami Khella⁵, Nisith Kumar^{4 6}, Michaela Liedtke⁷, Isabelle Lousada⁸, Tiffany Patrick ^{4 9}, Colleen Moffitt^{4 9}, Lori Klein¹⁰, Gabriela Tamariz^{4 9}, Karthikeyan Veeraraghavalu^{4 11}, Alexandra Haddad-Angulo^{4 6}

Affiliations

¹Mayo Clinic, FL, USA; ²Duke University Hospital, NC, USA; ³BridgeBio, CA, USA; ⁴Amyloidosis Reserach Consortium (ARC) - Amyloidosis Stakeholder Partnerships for Impact, Reach & Equity (ASPIRE), MA, USA; ⁵University of Pennsylvania School of Medicine, PA, USA; ⁶Pfizer Inc, NY, USA; ⁷Stanford Health Care, CA, USA; ⁸Amyloidosis Research Consortium (ARC), MA, USA; ⁹Alnylam Pharmaceuticals, MA, USA; ¹⁰Putnam Associates, MA, USA; ¹¹Prothena Biosciences Inc, CA, USA

Abstract

Objectives:

Amyloidosis is a group of rare diseases that often manifest in multi-organ symptoms requiring an effective multidisciplinary team of care providers to manage. This study aimed to identify the best practices and key barriers to patient-centric care at US specialized amyloidosis centers (SACs) which have emerged as central hubs for multidisciplinary amyloidosis care.

Methods:

We conducted and analyzed interviews with 77 stakeholders of amyloidosis diseases, including specialist physicians from 17 SACs across the US, patients, patient advocacy group representatives, and referring physicians.

Results:

The most commonly mentioned best practices were patient-centric multidisciplinary care, timely intake of new high-risk patients, and responsiveness to patient questions. Expanding local physician education was noted as critical to earlier diagnosis. Fifteen out of 17 SACs are actively involved in clinical trials for amyloidosis treatments. Key barriers to care identified were patient distance to SACs, limited medical records and data sharing, and insurance hurdles. Most SACs keep track of metrics, such as patient volume, patient demographics, time to first appointment, as part of internal or in external registries to measure progress.

Conclusions:

These findings offer practical insights for optimizing amyloidosis care and highlight the structural and informational gaps that must be addressed to improve access and outcomes.